title: Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization.
abstract: The molecular pathogenesis as well as histogenesis of endocrine pancreatic tumors (EPTs) is not well understood, and the clinical behavior of EPTs is difficult to predict using current morphological criteria. Thus, more accurate markers of risk and better understanding of tumor initiation and progression are needed to allow a precise classification of EPTs. We have studied 44 benign and malignant EPTs by comparative genomic hybridization to correlate the overall number of genetic alterations with clinical and histopathological parameters and to identify chromosomal regions which might harbor genes involved in EPT pathogenesis and progression. Aberrations were found in 36 EPTs, and chromosomal losses (mean, 5.3) were slightly more frequent than gains (mean, 4. 6). The most frequent losses involved Y (45% of male EPTs), 6q (39%), 11q (36%), 3p, 3q, 11p (each 30%), 6p (27%), and 10q and Xq (each 25%), whereas most common gains included 7q (43%), 17q (41%), 5q and 14q (each 32%), 7p, 9q, 17p, 20q (each 27%), and 12q and Xp (each 25%). A correlation was found between the total number of genetic changes per tumor and both tumor size and disease stage. In particular, losses of 3p and 6 and gains of 14q and Xq were found to be associated with metastatic disease. Furthermore, characteristic patterns of genetic changes were found in the various EPT subtypes, eg, 6q loss in malignant insulinomas, indicating that these groups might evolve along genetically different pathways. The highlighted genetic aberrations, including the newly found involvement of 6q losses and sex chromosome alterations, should stimulate the further analysis of these chromosomal regions, which may lead to the discovery of novel genes important in the tumorigenesis and evolution of EPTs.
authors.affiliation: Department of Pathology, University of Zürich, Zürich, Switzerland. ernst-jan.speel@pty.usz.ch
authors.forename: E J
authors.initials: EJ
authors.lastname: Speel
authors.forename: J
authors.initials: J
authors.lastname: Richter
authors.forename: H
authors.initials: H
authors.lastname: Moch
authors.forename: C
authors.initials: C
authors.lastname: Egenter
authors.forename: P
authors.initials: P
authors.lastname: Saremaslani
authors.forename: K
authors.initials: K
authors.lastname: Rütimann
authors.forename: J
authors.initials: J
authors.lastname: Zhao
authors.forename: A
authors.initials: A
authors.lastname: Barghorn
authors.forename: J
authors.initials: J
authors.lastname: Roth
authors.forename: P U
authors.initials: PU
authors.lastname: Heitz
authors.forename: P
authors.initials: P
authors.lastname: Komminoth
mesh_terms: D002869:Chromosome Aberrations; D004273:DNA, Neoplasm / Q000032:analysis*; D005260:Female; D016147:Genes, Tumor Suppressor; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008297:Male; D008677:Metaphase; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009693:Nucleic Acid Hybridization; D009857:Oncogenes; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000473:pathology*
chemical_list: D004273:DNA, Neoplasm